BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lessig S, Ubhi K, Galasko D, Adame A, Pham E, Remidios K, Chang M, Hansen LA, Masliah E. Reduced hypocretin (orexin) levels in dementia with Lewy bodies. Neuroreport 2010;21:756-60. [PMID: 20531237 DOI: 10.1097/WNR.0b013e32833bfb7c] [Cited by in Crossref: 21] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Abbott SM, Videnovic A. Sleep Disorders in Atypical Parkinsonism. Mov Disord Clin Pract 2014;1:89-96. [PMID: 24955381 DOI: 10.1002/mdc3.12025] [Cited by in Crossref: 32] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
2 Wilson H, Giordano B, Turkheimer FE, Chaudhuri KR, Politis M. Serotonergic dysregulation is linked to sleep problems in Parkinson's disease. Neuroimage Clin 2018;18:630-7. [PMID: 29845011 DOI: 10.1016/j.nicl.2018.03.001] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 6.3] [Reference Citation Analysis]
3 Gan J, Chen Z, Han J, Ma L, Liu S, Wang XD, Ji Y. Orexin-A in Patients With Lewy Body Disease: A Systematic Review and Meta-Analysis. Front Endocrinol (Lausanne) 2021;12:765701. [PMID: 34867809 DOI: 10.3389/fendo.2021.765701] [Reference Citation Analysis]
4 Stern AL, Naidoo N. Wake-active neurons across aging and neurodegeneration: a potential role for sleep disturbances in promoting disease. Springerplus 2015;4:25. [PMID: 25635245 DOI: 10.1186/s40064-014-0777-6] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 4.3] [Reference Citation Analysis]
5 Schmidt FM, Kratzsch J, Gertz HJ, Tittmann M, Jahn I, Pietsch UC, Kaisers UX, Thiery J, Hegerl U, Schönknecht P. Cerebrospinal fluid melanin-concentrating hormone (MCH) and hypocretin-1 (HCRT-1, orexin-A) in Alzheimer's disease. PLoS One 2013;8:e63136. [PMID: 23667582 DOI: 10.1371/journal.pone.0063136] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 4.3] [Reference Citation Analysis]
6 Azhar L, Kusumo RW, Marotta G, Lanctôt KL, Herrmann N. Pharmacological Management of Apathy in Dementia. CNS Drugs 2022. [PMID: 35006557 DOI: 10.1007/s40263-021-00883-0] [Reference Citation Analysis]
7 Al-Kuraishy HM, Abdulhadi MH, Hussien NR, Al-Niemi MS, Rasheed HA, Al-Gareeb AI. Involvement of orexinergic system in psychiatric and neurodegenerative disorders: A scoping review. Brain Circ 2020;6:70-80. [PMID: 33033776 DOI: 10.4103/bc.bc_42_19] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
8 Jiang H, Huang J, Shen Y, Guo S, Wang L, Han C, Liu L, Ma K, Xia Y, Li J, Xu X, Xiong N, Wang T. RBD and Neurodegenerative Diseases. Mol Neurobiol 2017;54:2997-3006. [PMID: 27032389 DOI: 10.1007/s12035-016-9831-4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
9 Rothman SM, Mattson MP. Sleep disturbances in Alzheimer's and Parkinson's diseases. Neuromolecular Med 2012;14:194-204. [PMID: 22552887 DOI: 10.1007/s12017-012-8181-2] [Cited by in Crossref: 51] [Cited by in F6Publishing: 44] [Article Influence: 5.1] [Reference Citation Analysis]
10 Ferman TJ, Smith GE, Dickson DW, Graff-Radford NR, Lin SC, Wszolek Z, Van Gerpen JA, Uitti R, Knopman DS, Petersen RC, Parisi JE, Silber MH, Boeve BF. Abnormal daytime sleepiness in dementia with Lewy bodies compared to Alzheimer's disease using the Multiple Sleep Latency Test. Alzheimers Res Ther 2014;6:76. [PMID: 25512763 DOI: 10.1186/s13195-014-0076-z] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 3.9] [Reference Citation Analysis]
11 Holth J, Patel T, Holtzman DM. Sleep in Alzheimer's Disease - Beyond Amyloid. Neurobiol Sleep Circadian Rhythms 2017;2:4-14. [PMID: 28217760 DOI: 10.1016/j.nbscr.2016.08.002] [Cited by in Crossref: 72] [Cited by in F6Publishing: 70] [Article Influence: 12.0] [Reference Citation Analysis]